Ms Jennifer Chu > Debevoise & Plimpton LLP > New York, United States > Lawyer Profile

Debevoise & Plimpton LLP is equally adept at advising life sciences clients on FDA regulations governing drugs and medical devices as it is assisting major private equity investors with acquisitions in the sector. The practice offers litigation services in relation to price fixing allegations and matters tied to the opioid epidemic. Andrew Bab, Jennifer Chu and Kevin Rinker handle the firm’s transactional workload, advising on the structuring of acquisitions and assisting with licensing issues. Mark Goodman represents clients in civil litigation and white collar trials, while also advising on internal investigations, with Maura Monaghan taking the lead on product liability and mass tort litigation. In Washington DC, Paul Rubin handles FDA matters, including compliance and regulatory enforcement, and is also recommended for carrying out due diligence processes for private equity houses. All lawyers are New York-based unless otherwise specified.

Predominantly working out of the New York office, Debevoise & Plimpton LLP‘s team is noted for its focus on private equity transactions within the healthcare and life sciences spaces. The group regularly advises on equity and debt financing arrangements, and class actions concerning overbilling practices. Key names within the team include corporate and M&A expert Andrew Bab, and Paul Rubin, who leads the FDA regulatory team from Washington DC. Mark Goodman and Maura Monaghan are noted for their expertise in commercial litigation, with Goodman standing out for his experience in handling white-collar crime matters and government investigations. Kevin Rinker and Jennifer Chu are both known for their expansive knowledge of M&A and private equity buyouts within the healthcare and life sciences sectors.

Representing domestic and international clients across the finance, aviation, and insurance sectors, the team at Debevoise & Plimpton LLP boasts a network of offices across the US and is highly adept at handling high-value cross-border M&A. Overseeing the San Francisco offering, global co-chair Michael Diz has broad-based transactional expertise, frequently advising public companies and special committees on complex governance issues, whilst the ‘top-notch’ Kevin Rinker co-heads the team from New York and is noted for advising on impactful transactions in the healthcare and banking sectors. Further key contacts in the New York office include Paul Bird, who is highly knowledgeable on leveraged buyouts, and Jennifer Chu, who focuses on joint ventures. Similarly based in New York, Jonathan Levitsky is an expert in the tech and media fields, while both William Regner and Jeffrey Rosen handle critical governance matters on behalf of global corporations.

Debevoise & Plimpton LLP offers clients ‘significant experience in the full range of PE transactions‘, including domestic and cross-border leveraged buyouts as well as PIPE deals, continuation fund transactions, and take-private acquisitions. Integrated cross-practice expertise in antitrust, tax, finance, and IP matters furthermore enables the team to guide clients through all stages of complexly structured acquisition, including joint governance matters as well as antitrust reviews. The New York-based team, which is particularly active across transactions in the healthcare and industrials sectors, is led by Kevin Schmidt, who stands out for his advice on cross-border acquisitions, joint ventures, and strategic investments. Experienced partner Paul Bird is noted for his M&A experience as well as his ability to handle spin-offs and takeover defense matters, and Kevin Rinker is a key contact for private equity deals in the healthcare and life sciences space. Further key contacts include Uri Herzberg and Jennifer Chu, who are sought out by leading funds such as Clayton, Dubilier & Rice in connection with high-value acquisitions, as well as Christopher Anthony, who handles a wide range of public and private M&A.